Tenderwize
Retour à la recherche

Non-exclusive rebate agreement for interferon beta-1a injection

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Erfurt, Germany·Deadline Apr 30, 2028 · 611 days left·Open·Supplies·Framework
Inscrivez-vous pour sauvegarderOpen documents
Titre original de l'avis

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Interferon beta-1a zur subkutanen Injektion (ATC-Code nach WHO: L03AB07)

62/100

Score d'opportunité

Needs reviewMedium complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

62 / 100

Complexité

58 / 100

Facteurs de risque

The notice says participation documents are to be submitted via the DTVP communication function, while also stating tha...

Eligibility is limited to pharmaceutical companies under Section 4(18) AMG for the offered product, and Russia-sanction...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Apr 2028
  • Conclusion of non-exclusive rebate agreements under Section 130a(8) SGB V for pharmaceutical products with active substance interferon beta-1a for subcutaneous injection.
  • Open-house participation model with no individual negotiations and no supply exclusivity.
Afficher le résumé complet

Open-house framework-style supply arrangement for non-exclusive pharmaceutical rebate agreements for interferon beta-1a for subcutaneous injection (CPV 33600000) led by AOK PLUS. The procedure is open to all eligible pharmaceutical companies during the participation period, with no individual negotiations and no exclusivity. Submission is electronic via DTVP communication functions, but the notice says the portal’s bidding tool is not used for submission in this open-house process. The contract runs until 30 April 2028 at the latest; no contract value is stated and minimum purchase volumes are not guaranteed.

Risques

The notice says participation documents are to be submitted via the DTVP communication function, while also stating tha...

Eligibility is limited to pharmaceutical companies under Section 4(18) AMG for the offered product, and Russia-sanction...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Applicant must be a pharmaceutical company within the meaning of Section 4(18) AMG for the offered medicinal product.
  • The company or its participating entity must not have a Russia-related link within the meaning of Article 5k of Regulation (EU) No 833/2014 as amended.

Eligibility

  • The self-declaration on the absence of exclusion grounds must be completed and submitted with the participation documents.

Acheteur

Localisation

Erfurt, DEU

Profil acheteur

Ouvrir le profil

Identifiant

DE256878834

Activité

Health

Lots (1)

LOT-0001

Non-exclusive rebate agreement for interferon beta-1a injection

Single lot covering the conclusion of non-exclusive pharmaceutical rebate agreements for medicines containing interferon beta-1a for subcutaneous injection. The lot is an open-house model, so any interested eligible pharmaceutical company may participate during the participation period. No exclusivity, no individual negotiations, and no guaranteed minimum purchase quantities are stated. Place of performance is Dresden, Germany.

SuppliesFrameworkEU fundedElectronic submission

Localisation

Dresden, Germany

Durée

Apr 2026 - Apr 2028

Catégorie

Pharmaceutical products

Date limite

Deadline Apr 30, 2028

Détails de la procédure

Date de publication
04 Mar 2026
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
155288-2026

Documents (1)

Document de consultation 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30